1 **Title page**

2 **Article category:** Short communication

3 **Recommended manuscript title**

4 Immunogenicity and Safety of Booster Dose of S-268019-b or Tozinameran in
5 Japanese Participants: An Interim Report of Phase 2/3, Randomized, Observer-
6 Blinded, Noninferiority Study

7
8 **Authors**

9 Masaharu Shinkai,¹ Takuhiro Sonoyama,² Akari Kamitani,² Risa Shibata,² Naomi
10 Seki,³ Shinya Omoto,³ Masahiro Shinoda,¹ Takashi Sato,¹ Naoki Ishii,⁴ Kenji
11 Igarashi,² Mari Ariyasu²

12
13 ¹Department of Respiratory Medicine, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
14 Shinagawa-ku, Tokyo 140-8522, Japan

15 ²Shionogi & Co., Ltd., Drug Development and Regulatory Science Division 8F,
16 Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042, Japan

17 ³Shionogi & Co., Ltd., Pharmaceutical Research Division 1-1, Futaba-cho 3-chome,
18 Toyonaka, Osaka 561-0825, Japan

19 ⁴Department of Gastroenterology, Tokyo Shinagawa Hospital, 6-3-22 Higashioi,
20 Shinagawa-ku, Tokyo 140-8522, Japan

21
22 **Corresponding author:** Mari Ariyasu

23 8F, Nissay Yodoyabashi East Bldg., 3-3-13, Imabashi, Chuo-ku, Osaka 541-0042,
24 Japan

25 Phone: +81-6-6209-6962

26 Fax: +81-6-6209-8047

27 Email: mari.tatsuno@shionogi.co.jp

28
29 Word count: 1983/2000

30 References: 19/20

31 Abstract word count: 150/150

32 Tables and multipanel figures: 4/4

33 Supplementary material: Appendix document, 5 tables, and 2 figures

34

35 **Abstract**

36 In this randomized, observer-blinded, phase 2/3 study, we assessed S-268019-b—a
 37 recombinant spike protein vaccine. We analyzed the noninferiority of S-268019-b
 38 (n=103), versus tozinameran (n=103), when given as a booster ≥6 months after the
 39 2-dose tozinameran regimen in Japanese adults without prior COVID-19 infection.
 40 Interim results showed that S-268019-b was noninferior to tozinameran in co-primary
 41 endpoints: geometric mean titer (GMT) (126.42 versus 108.20; adjusted-GMT ratio
 42 [95% CI], 1.17 [0.96-1.42]; noninferiority *P*-value, <0.0001) and seroresponse rate
 43 (both 100%; noninferiority *P*-value, 0.0004) for neutralizing antibodies on day 29.
 44 Both vaccines elicited anti-spike protein immunoglobulin G antibodies, and produced
 45 T-cell response (n=30/group) and neutralized Delta and Omicron pseudovirus
 46 variants (n=24/group) in subgroups. Most participants reported low-grade
 47 reactogenicity on days 1 and 2, the most frequent being fatigue, fever, myalgia, and
 48 injection-site pain. No serious adverse events were reported. S-268019-b safety and
 49 robust immunogenicity as a booster, supporting its use as COVID-19 booster
 50 vaccine.

51

52 **Keywords:** booster, clinical trial, neutralization test, SARS-CoV-2, recombinant
 53 spike protein, immunization

54

55 **JRCT ID:** jRCT2031210470

56 **Highlights**

- 57 • Third COVID-19 vaccine dose (booster) enhances immune response
- 58 • Interim phase 2/3 data for booster ≥ 6 months after the 2nd dose in Japan are
- 59 shown
- 60 • S-268019-b and tozinameran were safe and equal in inducing neutralizing
- 61 antibodies
- 62 • Both boosters neutralized Delta and Omicron pseudovirus and induced T-cell
- 63 response
- 64 • Results support use of S-268019-b as a booster in vaccinated adults

65 Introduction

66 Cases of coronavirus disease 2019 (COVID-19) caused by severe acute
67 respiratory syndrome coronavirus 2 (SARS-CoV-2) are increasing periodically
68 because of several reasons. A third vaccine dose (booster) is recommended
69 because of concerns regarding waning humoral immunity over 6 months after the
70 second dose [1] and consequent reduced effectiveness against SARS-CoV-2
71 infection [2], as well as threats from new mutant strains that may escape the
72 vaccine-mediated immunity. Booster immunization can substantially improve the
73 humoral immune response against the emerging variants, including Omicron [3], [4].

74 Shionogi & Co., Ltd., has developed a novel vaccine candidate—S-268019-
75 b—comprising a modified recombinant spike protein of SARS-CoV-2 (S-910823,
76 antigen) produced using the baculovirus expression system in insect cells and a
77 squalene-based adjuvant (A-910823). In a double-blinded, phase 1/2 trial, S-268019-
78 b showed tolerability and a robust immunogenic response 4 weeks after the second
79 dose [5, Unpublished results]. Here, we present the interim results of a phase 2/3,
80 randomized trial, wherein the immunogenicity and safety of a single booster dose of
81 S-268019-b or tozinameran were assessed in Japan.

83 Methods

84 *Study design and participants*

85 This phase 2/3, single-center, randomized, observer-blinded, active-
86 controlled, noninferiority trial comprised three periods: screening (day -28 to -1),
87 evaluation (day 1 to 29), and follow-up (day 30 to 365) (**Figure 1**).

88 Participants were healthy immunocompetent Japanese adults (aged ≥ 20 years)
89 who had received two doses of tozinameran (BNT162b2; Pfizer/BioNTech mRNA
90 vaccine), with the second dose received ≥ 6 months ago. Individuals with laboratory-
91 confirmed SARS-CoV-2 infection at screening or known history of SARS-CoV-2
92 infection were excluded (See **Supplementary Methods** for details).

93 Eligible participants were randomized 1:1, stratified by age (<40 and ≥ 40
94 years) and sex, to receive an intramuscular injection of either 0.5 mL of S-268019-b
95 (10 μ g antigen prepared with 50% v/v oil-in-water adjuvant emulsion) or 0.3 mL of
96 tozinameran (30 μ g in saline) on day 1.

97 The study (jRCT2031210470) was conducted in compliance with the protocol,
98 the Declaration of Helsinki and Council for International Organizations of Medical

Sciences International Ethical Guidelines, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines, other applicable laws and regulations, and was approved by Institutional Review Board of Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai. All participants gave their written informed consent.

Outcomes

The primary objective of the study was to assess the noninferiority of S-268019-b versus tozinameran as a booster dose in inducing SARS-CoV-2 neutralizing antibodies on day 29. The co-primary endpoints included day 29 geometric mean titer (GMT) and seroresponse rate (SRR) for SARS-CoV-2 neutralizing antibodies. SRR was defined as the proportion of participants with a post-vaccination antibody titer ≥ 4 -fold higher than the baseline.

Secondary endpoints comprised other immunogenicity parameters and safety. These included GMT, geometric mean fold rise (GMFR), and SRR for neutralizing antibodies and anti-spike protein immunoglobulin G (IgG) antibodies on days 15 and 29. Exploratory analyses in a smaller sample included geometric means of 50% neutralization titer (NT_{50}) against SARS-CoV-2 pseudovirus strains (wildtype [D614G], Delta, and Omicron) on day 29 and T-cell response on day 15. Safety endpoints included incidence of adverse events (AEs), serious AEs, AEs of special interest, treatment-related AEs (TRAEs), medically attended TRAEs, solicited TRAEs, and changes in laboratory test values. Immunogenicity variables with titer values below the lower limit of quantification (LLOQ) were replaced with $0.5 \times \text{LLOQ}$.

Statistical analyses

The study used a noninferiority design. Noninferiority of S-268019-b to tozinameran is confirmed when the lower limit of 95% CI is >0.67 for GMT ratio (S-268019-b/tozinameran) derived from the analysis of covariate model with age and sex as covariates, and more than -10% for SRR difference (S-268019-b minus tozinameran) by the Farrington-Manning method for neutralizing antibodies on day 29 [6]. The immunogenicity subset included participants who received ≥ 1 dose of the study intervention, had ≥ 1 post-vaccination immunogenicity data, and were negative for anti-SARS-CoV-2 N-protein antibody at screening. The safety analysis subset

included participants who received ≥ 1 dose of the study intervention. All analyses were conducted based on the actual intervention administered.

Data were summarized using measures of central tendency, dispersion, and frequency distribution. Unless otherwise noted, all statistical tests were performed at the two-sided $\alpha=0.05$. Missing values were not imputed. All analyses were performed using SAS[®] v9.4 (SAS Institute, NC, USA). (See **Supplementary Appendix** for detailed methods and statistical analyses).

Results

Trial Participants

All 206 participants screened were enrolled in the study (S-268019-b, n=103; tozinameran, n=103) during December 3–22, 2021 (**Supplementary Figure 1**). Baseline demographics and participant characteristics were balanced across S-268019-b and tozinameran groups: median age (range) was 30.0 (21-59) and 31.5 (21-60) years; male population, 70% and 72%, respectively (**Supplementary Table 1**).

Immunogenicity

Per day 29 analysis, both co-primary endpoints were met: as a booster, S-268019-b was noninferior to tozinameran in SARS-CoV-2 neutralization. GMTs (95% CIs) for neutralizing antibodies at baseline were 5.53 (4.87-6.28) for S-268019-b group and 6.70 (5.76-7.78) for tozinameran, which increased to 126.42 (109.76-145.62) and 108.20 (94.57-123.80), respectively, by day 29 (adjusted-GMTR 1.17; 95% CI 0.96-1.42; one-sided *P*-value for noninferiority, <0.0001). The SRR was 100% for both groups (SRR difference 0.0; 95% CI -5.8 to 5.8 ; one-sided *P*-value for noninferiority, 0.0004) (**Figure 2A and Table 1**). The GMTs (95% CIs) for anti-spike protein IgG antibodies at baseline were 1475.9 (1280.1-1701.6) for S-268019-b and 1795.9 (1536.9-2098.6) for tozinameran; these were elevated to 48844.0 (41855.3-56999.7) and 55214.8 (49013.5-62200.7), respectively, on day 29 (**Figure 2B**), with both groups showing 100% SRR (**Supplementary Table 2**). The GMFR and GMT results were consistent (**Supplementary Table 2 and Figure 2**).

Furthermore, the geometric mean NT₅₀ against SARS-CoV-2 pseudovirus variants on day 29 were assessed in a smaller sample of the immunogenicity subset

(n=24/group). The sampling ensured no significant differences in age and neutralizing antibody titer against live wildtype virus on day 29 compared with the entire cohort (**Supplementary Table 3**). Serum samples from both vaccine groups neutralized Delta and Omicron pseudovirus variants with similar potency, as indicated by NT₅₀ values relative to tozinameran (**Figure 2C**). T-cell responses were assessed for a subgroup (n=30/group) sampled from participants who gave consent for cellular immunity assessments. Both vaccines induced antigen-specific polyfunctional CD4⁺ T-cell responses, as reflected in the interferon-gamma and interleukin-2 expression on day 15 (**Supplementary Figure 2**). A strong bias toward the T-helper type 1 phenotype was noted.

Safety

Both, S-268019-b and tozinameran, displayed an acceptable safety profile as a booster. There were no treatment-emergent serious AEs, deaths, grade 4-5 solicited TRAEs, or AEs of special interest reported until data cutoff date (February 4, 2022) (**Supplementary Table 4**). Overall, 96.1% (99/103) participants reported 375 TRAEs in the S-268019-b group, and 98.1% (101/103) participants reported 464 TRAEs in the tozinameran group. Furthermore, solicited systemic TRAEs were reported by 69.9% (72/103) and 78.6% (81/103) participants and solicited local TRAEs by 68.0% (70/103) and 72.8% (75/103) participants in the S-268019-b and tozinameran groups, respectively. The most frequently reported solicited TRAEs within 7 days in both booster groups were injection-site pain, fatigue, fever, myalgia, and headache (**Table 2**). Most of the solicited TRAEs were grade 1-2 and were reported on day 1-2 of the booster dose injection (**Supplementary Table 5**). One participant in the S-268019-b group and four participants in the tozinameran group experienced grade 3 solicited TRAEs.

Discussion

This study showed that S-268019-b as a booster (third) dose was noninferior to tozinameran in inducing SARS-CoV-2 neutralizing antibodies. Both vaccines induced neutralizing antibodies against pseudovirus variants, and also elicited anti-spike protein IgG antibodies and T-cell responses within a month after the booster dose.

In other booster-dose studies, a third dose of either homologous or heterologous vaccines administered 3-9 months after the initial vaccination elicited robust immunogenicity against SARS-CoV-2 variants [7], [8], [9], [10], [11], [12]. In the COV-BOOST trial, immunogenicity of various types of vaccines given as the third dose was assessed in participants with primary vaccination with either tozinameran or AZD-1222 [12]. While the booster dose of all types of vaccines (mRNA, protein subunit, adenovirus vector, and inactivated virus) amplified immune responses, mRNA vaccines (tozinameran and mRNA-1273) induced more potent immunogenicity than other types of vaccines [12]. Considering that S-268019-b booster is as immunogenic as the tozinameran booster, S-268019-b may elicit more potent humoral immunogenicity than other types of vaccines in the COV-BOOST study, although a direct comparison is not possible.

Although no correlates of protection have been established in COVID-19, the neutralizing antibody titer against SARS-CoV-2 after primary vaccination is highly correlated with clinical efficacy against symptomatic COVID-19 [13]. Humoral immunity in COVID-19 is known to wane over time, especially after 6 months [1], and so does protection against symptomatic COVID-19 [2]. In this study, lower baseline titers for neutralizing antibodies ≥ 6 months after the 2-dose tozinameran vaccination were observed, consistent with previous reports. Meanwhile, studies have reported that a booster dose of tozinameran after 2 doses of tozinameran enhances humoral immunity [7], [12]. Moreover, a report from Israel stated greater efficacy against COVID-19-related hospitalization and death after three versus two tozinameran doses [14]. Since our results show noninferiority of S-268019-b to tozinameran in inducing neutralizing antibodies, it is speculated that S-28019-b may also show clinical efficacy similar to the booster tozinameran, although further investigations to support this theory are warranted.

A previous study showed that the NT_{50} against the live Omicron virus after two doses of tozinameran was below the detection limit and 61-fold lower compared with the wildtype NT_{50} [15]. However, the third (booster) dose of tozinameran elicited neutralizing antibody titer against Omicron, with NT_{50} only 6-fold lower than that with the wildtype [15]. Moreover, the tozinameran booster dose protected against symptomatic COVID-19 due to Omicron [16]. The current findings showing that S-268019-b and tozinameran are similar with respect to neutralizing antibody levels

against Omicron suggest that S-28019-b might also show similar clinical efficacy against symptomatic COVID-19 due to Omicron.

The T-cell response in COVID-19 is crucial for sustained protection from severe disease progression [17], [18]. Additionally, the T-cell response elicited by COVID-19 infection or prior vaccination is considered cross-reactive against other variants, including Omicron [19]. In the current study, we only examined the T-cell response to the original wildtype strain, in which S-268019-b showed a response similar to tozinameran. However, due to the cross-reactive nature of the T-cell response, it is speculated that the T-cell response elicited by S-268019-b may possibly be effective in preventing severe diseases caused by Omicron and other future variants.

In this study, both vaccines led to mainly low-grade reactogenicity, with fever, fatigue, myalgia, and injection-site pain being commonly reported, usually within 2 days of the booster dose. Compared with tozinameran, S-268019-b led to a lower incidence of solicited TRAEs. Similarly, across all 7 booster vaccines in the COV-BOOST trial, the most frequently solicited AEs reported within 7 days were low-grade fatigue, headache, and local pain [12]. Despite the differences in population and methodologies across different studies, reactogenicity patterns seem largely consistent across studies after the booster dose of either an mRNA [7], [8], adenovirus vector [9], or protein subunit vaccine [10], [11], [12].

This is the first clinical trial report of a recombinant spike protein vaccine showing its noninferiority to an mRNA vaccine as a booster dose in Japanese participants. Some limitations of this study must however be acknowledged. The study (1) was designed for an immunocompetent adult Japanese cohort with no known history of SARS-CoV-2 infection and prior vaccination with only tozinameran, and (2) has a short follow-up duration for interim analysis and relatively small sample size. Also, this study was not powered to demonstrate clinical efficacy. Despite these limitations, a booster dose of the recombinant spike protein vaccine, S-268019-b, elicited robust immunogenicity against SARS-CoV-2, with mostly low-grade reactogenicity.

Conclusion

The booster dose of S-268019-b vaccine was noninferior to tozinameran booster as per the findings of GMT and SRR for SARS-CoV-2 neutralizing

antibodies, and was well-tolerated in fully vaccinated adult Japanese participants. S-268019-b booster was comparable with tozinameran booster in neutralizing the pseudovirus variants, Delta and Omicron. Thus, S-268019-b might be a future option for COVID-19 booster vaccine in adults.

Funding: This work was supported by Shionogi & Co., Ltd., and Ministry of Health, Labour and Welfare (MHLW) under its supplementary budget for emergency maintenance associated with the vaccine production system. Preparation of clinical trial materials of S-268019-b was supported by Japan Agency for Medical Research and Development (AMED) under Grant Number JP21nf010626.

Acknowledgments: The authors thank Ms. Kiyomi Kabasawa, Ms Wakana Abe, Ms Harue Otsuka, Ms. Emi Kawabe, Ms. Narumi Iida, and Ms Etsuko Tanaka for supporting clinical trials as clinical research coordinator, and Dr. Kenichi Kamachi and all the staff of Tokyo Shinagawa Hospital for supporting the clinical trials, and Ms. Haruna Hayashi and Mr. Satoshi Kojima (Shionogi & Co., Ltd.) for supporting manuscript development. The authors also thank Dr. Minal Jaggar, PhD, Dr. Vidula Bhole, MD, MHSc, and Mr. Ivan D'Souza, MS, of MedPro Clinical Research for providing medical writing support for this manuscript, which was funded by Shionogi & Co., Ltd.

Disclosures/potential conflicts of interests

M. Shinkai, M. Shinoda, T. Sato, and N. Ishii have no conflicts of interest to declare. TS, AK, RS, NS, SO, KI, and MA are employees of Shionogi & Co., Ltd.

References

- [1] Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N Engl J Med* 2021;385:e84. <https://doi.org/10.1056/nejmoa2114583>
- [2] Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. *Lancet* (London, England) 2021;398:1407–16. [https://doi.org/10.1016/S0140-6736\(21\)02183-8](https://doi.org/10.1016/S0140-6736(21)02183-8)
- [3] Garcia-Beltran WF, St. Denis KJ, Hoelzemer A, Lam EC, Nitido AD, Sheehan ML, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. *Cell* 2022;185:457–66. <https://doi.org/10.1016/J.CELL.2021.12.033>
- [4] Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. *Nat Med* 2022:1–4. <https://doi.org/10.1038/s41591-021-01676-0>
- [5] Iwata S, Sonoyama T, Kamitani A, Shibata R, Homma T, Omoto S, et al. Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: a report of interim findings. [Vaccine: Submitted].
- [6] Office of Vaccines and Blood Products, Pharmaceuticals and Medical Device Agency, Japan. Principles for the evaluation of vaccines against the novel coronavirus SARS-CoV-2 (Appendix 3). <https://www.pmda.go.jp/files/000243339.pdf>; 2021 [accessed 25 February 2022].
- [7] Falsey AR, Frenck RW, Walsh EE, Kitchin N, Absalon J, Gurtman A, et al. SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3. *N Engl J Med* 2021;385:1627–9. <https://doi.org/10.1056/NEJMc2113468>
- [8] Choi A, Koch M, Wu K, Chu L, Ma L, Hill A, et al. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med* 2021;27:2025–31. <https://doi.org/10.1038/s41591-021-01527-y>
- [9] Flaxman A, Marchevsky NG, Jenkin D, Aboagye J, Aley PK, Angus B, et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). *Lancet* 2021;398:981–90. [https://doi.org/10.1016/S0140-6736\(21\)01699-8](https://doi.org/10.1016/S0140-6736(21)01699-8)
- [10] Mallory R, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al. Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a phase 2 randomized placebo-controlled trial. *MedRxiv* 2021:2021.12.23.21267374. <https://doi.org/10.1101/2021.12.23.21267374>
- [11] Cao Y, Hao X, Wang X, Wu Q, Song R, Zhao D, et al. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two

- 334 doses of inactivated vaccine. *Cell Res* 2021;32:107–9.
335 <https://doi.org/10.1038/s41422-021-00596-5>
- 336 [12] Munro APS, Janani L, Cornelius V, Aley PK, Babbage G, Baxter D, et al.
337 Safety and immunogenicity of seven COVID-19 vaccines as a third dose
338 (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK
339 (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
340 *Lancet* 2021;398:2258–76. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02717-3)
341 [6736\(21\)02717-3](https://doi.org/10.1016/S0140-6736(21)02717-3)
- 342 [13] Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al.
343 Neutralising antibody titres as predictors of protection against SARS-CoV-2
344 variants and the impact of boosting: a meta-analysis. *The Lancet Microbe*
345 2022;3:e52–61. [https://doi.org/10.1016/S2666-5247\(21\)00267-6](https://doi.org/10.1016/S2666-5247(21)00267-6)
- 346 [14] Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al.
347 Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for
348 preventing severe outcomes in Israel: an observational study. *Lancet*
349 (London, England) 2021;398:2093–100. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)02249-2)
350 [6736\(21\)02249-2](https://doi.org/10.1016/S0140-6736(21)02249-2)
- 351 [15] Muik A, Lui BG, Wallisch A-K, Bacher M, Mühl J, Reinholz J, et al.
352 Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited
353 human sera. *Science* 2022;375:678–80.
354 <https://doi.org/10.1126/science.abn7591>
- 355 [16] Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, et al.
356 Association between 3 doses of mRNA COVID-19 vaccine and symptomatic
357 infection caused by the SARS-CoV-2 Omicron and Delta variants. *JAMA*.
358 2022;327(7):639–51. <https://doi.org/10.1001/jama.2022.0470>
- 359 [17] Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell
360 and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term
361 immune responses in COVID-19 convalescent individuals. *Sci Transl Med*
362 2021;13:7517. <https://doi.org/10.1126/scitranslmed.abf7517>
- 363 [18] Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol*
364 2022;23:186–93. <https://doi.org/10.1038/s41590-021-01122-w>
- 365 [19] Gao Y, Cai C, Grifoni A, Müller TR, Niessl J, Olofsson A, et al. Ancestral
366 SARS-CoV-2-specific T cells cross-recognize the Omicron variant. *Nat Med*
367 2022:1–5. <https://doi.org/10.1038/s41591-022-01700-x>

Figure legends

Figure 1: Study design, vaccine regimen, and key assessments

NT₅₀, 50% neutralization titer.

Figure 2: GMTs in the tozinameran and S-268019-b groups for (A) neutralizing antibodies against live wildtype virus by cytopathic effect, (B) anti-spike protein IgG, and (C) relative NT₅₀ against pseudotyped virus variants

GMT, geometric mean titer; IgG, immunoglobulin G; LLOQ, lower limit of quantification; NT₅₀, 50% neutralization titer.

Data are presented as GMTs and 95% CIs. In Figure 2C, white and grey circles represent individual relative NT₅₀ values for the tozinameran (n=24) and S-268019-b (n=24) groups, respectively, relative to group GMT for tozinameran, on day 29.

Titer values reported as below the LLOQ were replaced with 0.5 × LLOQ. The LLOQ was 5 for neutralizing antibodies and 100 for anti-spike protein IgG. The 95% CI were constructed using Student's *t* distribution for log-transformed titers.

Supplementary Figure 1: Participant flow

Supplementary Figure 2: Immunologic assays from PBMCs for percent of CD4⁺ T cells positive for IFN- γ , IL-2, IL-4, and IL-5 at baseline and on day 15 in the study groups

IFN, interferon; IL, interleukin; PBMCs, peripheral blood mononuclear cells.

Data are presented as mean and 95% CI. Dark circles represent baseline and light squares represent day 15 values of immune marker expression for individual participants in the study groups (n=30/group). The 95% CI were constructed using the Clopper-Pearson method for proportion data.

Table 1: Co-primary endpoints (GMT and SRR) with GMTR and SRR difference in SARS-CoV-2 neutralizing antibody response on day 29, and GMT and SRR at baseline and on day 15

Outcome (95% CI)	Tozinameran (n=101)			S-268019-b (n=103)		
	Baseline ^a	Day 15	Day 29	Baseline	Day 15	Day 29
GMT ^b	6.70 (5.76, 7.78)	138.53 (121.61, 157.80)	108.20 (94.57, 123.80)	5.53 (4.87, 6.28)	128.14 (112.79, 145.57)	126.42 (109.76, 145.62)
GMTR ^c	-	-	-	-	-	1.17 (0.96, 1.42)
SRR ^d	-	99.0 (94.6, 100.0)	100.0 (96.4, 100.0)	-	100.0 (96.5, 100.0)	100.0 (96.5, 100.0)
SRR difference ^d	-	-	-	-	-	0.0 (-5.8, 5.8)

GMT, geometric mean titer; GMTR, geometric mean titer ratio; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SRR, seroresponse rate.

Criteria for noninferiority confirmed when lower limit of 95% CI >0.67 for GMTR (S-268019-b/tozinameran) and > -10% for SRR difference (S-268019-b – tozinameran).

^aAt baseline, tozinameran group had 102 participants. ^bThe GMTs with corresponding 95% CIs were estimated by back transformation from the arithmetic mean and the 95% CIs based on the Student's *t* distribution of log-transformed titers to the original scale. ^cThe GMTR and its 95% CI were obtained using analysis of covariance model fitted on the log-transformed titers; the model included intervention group as the fixed effect as well as age (continuous) and sex as covariates. ^dThe 95% CI were constructed using the Clopper-Pearson method for SRR and the Farrington-Manning method for SRR difference.

413 **Table 2:** Incidence of solicited local and systemic treatment-related adverse events (experienced within 7 days after the booster) by
414 severity in the study groups

	Tozinameran (n=103)				S-268019-b (n=103)			
	Any grade	Grade 1	Grade 2	Grade 3	Any grade	Grade 1	Grade 2	Grade 3
Any systemic solicited TRAEs	81 (78.6)	46 (44.7)	31 (30.1)	4 (3.9)	72 (69.9)	56 (54.4)	15 (14.6)	1 (1.0)
Fatigue	55 (53.4)	32 (31.1)	22 (21.4)	1 (1.0)	45 (43.7)	36 (35.0)	9 (8.7)	-
Fever	61 (59.2)	52 (50.5)	7 (6.8)	2 (1.9)	40 (38.8)	37 (35.9)	2 (1.9)	1 (1.0)
Myalgia	49 (47.6)	42 (40.8)	7 (6.8)	-	42 (40.8)	41 (39.8)	1 (1.0)	-
Headache	43 (41.7)	31 (30.1)	12 (11.7)	-	26 (25.2)	19 (18.4)	7 (6.8)	-
Arthralgia	12 (11.7)	7 (6.8)	5 (4.9)	-	8 (7.8)	6 (5.8)	2 (1.9)	-
Nausea/vomiting	5 (4.9)	5 (4.9)	-	-	5 (4.9)	4 (3.9)	1 (1.0)	-
Diarrhea	6 (5.8)	4 (3.9)	1 (1.0)	1 (1.0)	4 (3.9)	3 (2.9)	1 (1.0)	-
Chills	7 (6.8)	3 (2.9)	4 (3.9)	-	4 (3.9)	2 (1.9)	2 (1.9)	-
Any local solicited TRAEs (at the injection site)	75 (72.8)	70 (68.0)	5 (4.9)	-	70 (68.0)	68 (66.0)	2 (1.9)	-
Pain	75 (72.8)	70 (68.0)	5 (4.9)	-	68 (66.0)	68 (66.0)	-	-
Erythema/redness	9 (8.7)	9 (8.7)	-	-	7 (6.8)	6 (5.8)	1 (1.0)	-
Swelling	1 (1.0)	1 (1.0)	-	-	1 (1.0)	-	1 (1.0)	-

415 TRAEs, treatment-related adverse events.

416 Data are presented as number (%) of the participants. No participants reported grade 4 or 5 solicited TRAEs.

Primary endpoints: geometric mean titer and seroresponse rate of neutralizing antibodies on day 29

Secondary endpoints: geometric mean titer, geometric mean fold rise and seroresponse rate of neutralizing antibodies and anti-spike protein IgG antibodies, incidence of adverse events (AEs), treatment-related AEs, serious AEs, solicited AEs, and changes in vital signs, laboratory test values and electrocardiograms

Exploratory endpoints: NT₅₀ against pseudovirus variants and T-cell cytokine assay

Screening

Evaluation

Follow-up

Healthy adults
vaccinated with
2 doses of
tozinameran
≥6 months ago
(age 20-60 years)

Randomization
(1:1)

Location: Japan

Candidate vaccine: 10 µg of S-268019-b in A-910823 (50% v/v)

Active-control: 30 µg of tozinameran in saline

Intramuscular injection
of booster (3rd) dose

Day
-28

Day
1

Day
15

Day
29

Day
365

Informed consent
and eligibility

Study site visit on days 2, 15, and 29 for investigations/examinations

Study site visit on days 69, 183,
and 365 for investigations/
examinations

A **B** **C**